Viewing nowPregatine Capsule 50 Milligram (Pregabalin)
Pregabalin 50mg
Hard capsule · Prescription medication
Hana Pharm Co., Ltd.

MFDS item code 201900612 · Approved 2019.01.23 · Insurance code 657806380
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunctive therapy for partial seizures in epilepsy patients, applicable regardless of the presence of secondary generalized symptoms. Additionally, it helps relieve symptoms in fibromyalgia patients. In summary, it is used for alleviating neuropathic pain, adjunctive therapy for partial seizures, and treatment of fibromyalgia.
This medicine is administered orally as pregabalin in 2 divided doses per day, regardless of food. Because this medicine is excreted mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys as unchanged drug. Because the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalinᵃ Administration schedule Initial dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30-<60: 75, 300, BID or TID ≥15-<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single doseᵇ TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: A supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because sufficient safety and efficacy data are not available. Adolescents aged 12-17 years: Administration is not recommended because sufficient safety and efficacy data are not available.
This medication is used as an anticonvulsant, and it may increase the risk of suicidal thoughts or behavior; therefore, if symptoms of depression or mood changes occur during treatment, consultation with a healthcare professional should be sought immediately. Patients with allergies to this drug's components or genetic lactose-related disorders should not take this medication. Diabetic patients may need to adjust their blood sugar control medications due to weight gain, and if angioedema symptoms occur, the medication should be discontinued immediately. Elderly patients should be cautious of the risk of falls due to dizziness or drowsiness, and visual impairments or changes in vision may occur. When discontinuing this medication, withdrawal symptoms such as insomnia, headaches, nausea, and anxiety may arise, so consultation with a healthcare professional is necessary. Patients with a history of drug abuse should be carefully monitored due to the potential for abuse with this medication. Patients with heart diseases or impaired kidney function should consult with a healthcare professional before taking this medication as dose adjustments may be necessary. Concomitant use of this drug and opioid analgesics can enhance central nervous system depression, posing risks such as respiratory depression, so caution is warranted. In early pregnancy, there may be a risk of fetal malformations; therefore, pregnant women are advised against taking this medication, and women of childbearing age should use effective contraceptive methods. Lactating women should consult with their healthcare provider about whether to discontinue breastfeeding due to the potential effects on the baby, as this medication may pass into breast milk. This medication may cause dizziness and drowsiness; therefore, caution is necessary when driving or operating dangerous machinery. In cases of overdose, confusion, drowsiness, depression, seizures, etc., may occur, requiring immediate medical attention. Store out of reach of children and do not transfer to another container for safety. If serious allergic reactions such as skin rashes, fever, or breathing difficulties occur during use, stop taking the medication immediately and visit a hospital.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. Additionally, for maintaining the drug's efficacy, it is advisable to keep it at room temperature between 15 to 30 degrees Celsius.
A hard capsule with a dark blue body and white cap that contains a white or pale yellow powder.
For domestic use - 30 capsules/bottle, For domestic use - 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 50mg
Hard capsule · Prescription medication
Hana Pharm Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.